Shares of MorphoSys AG (ETR:MOR) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is €74.71 ($88.95).

Several research analysts have issued reports on MOR shares. Commerzbank Ag set a €76.00 ($90.48) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a research report on Tuesday, June 6th. Berenberg Bank set a €68.00 ($80.95) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Friday, July 14th. HSBC Holdings plc set a €59.00 ($70.24) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a research report on Friday, July 14th. Finally, Independent Research GmbH set a €77.00 ($91.67) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Monday, July 17th.

Shares of MorphoSys AG (ETR:MOR) traded down 1.11% during midday trading on Friday, reaching €71.20. The company’s stock had a trading volume of 1,701 shares. The stock’s market capitalization is €2.06 billion. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €72.59. The stock’s 50 day moving average is €60.74 and its 200 day moving average is €59.75.

TRADEMARK VIOLATION WARNING: “MorphoSys AG (MOR) Given Consensus Recommendation of “Buy” by Brokerages” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/morphosys-ag-mor-given-consensus-recommendation-of-buy-by-brokerages/1598521.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.